BioPharmSignal logoBioPharmSignal

Biotech News

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics (TARA)Protara TherapeuticsEarnings

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q 2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H

Related news

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

View all latest news

Protara Therapeutics

Cancer and Rare-Disease Company Protara Therapeutics develops therapies for cancer and rare diseases, with programs spanning cell-based immunopotentiation and phospholipid substrate replacement. Bladder Cancer The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle-invasive bladder cancer across BCG-unresponsive,...

Recent company news

TARAProtara Therapeutics2026-11-06 13:00 EST

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-10-15 12:00 EST

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-05-20 12:00 EST

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Stock data

Close
2.13 USD
Market cap
243.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States